Panolos Bioscience is a frontrunner in structure-based protein design and development, with a focus on multi-specific drug development. We specialize in creating anti-angiogenic therapies targeting cancer, autoimmune, and rare diseases. Our proprietary "Alpha(α)-ART (Anti-angiogenesis-based Artifact Re-targeting Tri-specific) technology" features a VEGF receptor backbone, enabling the creation of mono- or multi-specific antibody therapeutics with enhanced efficacy. Starting October 2023, PB101 using αART technology is enrolling for Phase I which is manufactured by Samsung Biologics based on a CDMO partnership. Panolos attracted a development partnership with Kelun-Biotech for PB203 (aka, PKB01), and formed the strategic alliance and CDMO partnership with Chime Biologics for the same. Panolos is developing various pipelines targeting PD-L1, EGFR, and TGF-beta(b) To support our ongoing development, Panolos Bioscience raised $18 million in Series A funding and is currently seeking a Series B Bridge investment of $20 million in 2023.
